Lin Qirui, Lei Defeng, Zhong Tongning, Zhang Yanmin, Da Qingen, Chen Xiao, Li Xuemei, Liu Jikui, Yan Zilong
Department of Hepatobiliary Surgery, Peking University Shenzhen Hospital Shenzhen 518000, Guangdong, China.
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University Kyoto 6068507, Japan.
Am J Cancer Res. 2024 Mar 15;14(3):1015-1032. doi: 10.62347/VPYE3817. eCollection 2024.
The ERK1/2 pathway is involved in epithelial-mesenchymal transformation and cell cycle of tumor cells in hepatocellular carcinoma (HCC). In the present study, we investigated the involvement of ERK1/2 activation on hepatic stellate cells (HSCs). We identified ERK1/2 phosphorylation in activated HSCs of HCC samples. We found that tumor cells promoted the migration and invasion capacity of HSCs by activating ERK1/2 phosphorylation. Using high throughput transcriptome sequencing analysis, we found that ERK1/2 inhibition altered genes significantly correlated to signaling pathways involved in extracellular matrix remodeling. We screened genes and demonstrated that the ERK1/2 inhibition-related gene set significantly correlated to cancer-associated fibroblast infiltration in TCGA HCC tumor samples. Moreover, inhibition of ERK1/2 suppressed tumor cell-induced enhancement of HSC migration and invasion by regulating expression of fibrosis markers FAP, FN1 and COL1A1. In a tumor cell and HSC splenic co-transplanted xenograft mouse model, inhibition of ERK1/2 suppressed liver tumor formation by downregulating fibrosis, indicating ERK1/2 inhibition suppresses tumor-stromal interactions . Taken together, our data indicate that inhibition of ERK1/2 in tumor-associated HSCs suppresses tumor-stromal interactions and progression. Furthermore, inhibition of ERK1/2 may be a potential target for HCC treatment.
ERK1/2信号通路参与了肝细胞癌(HCC)肿瘤细胞的上皮-间质转化和细胞周期。在本研究中,我们调查了ERK1/2激活对肝星状细胞(HSCs)的影响。我们在HCC样本的活化HSCs中鉴定出了ERK1/2磷酸化。我们发现肿瘤细胞通过激活ERK1/2磷酸化促进了HSCs的迁移和侵袭能力。通过高通量转录组测序分析,我们发现ERK1/2抑制改变了与细胞外基质重塑相关信号通路显著相关的基因。我们筛选了基因,并证明在TCGA HCC肿瘤样本中,ERK1/2抑制相关基因集与癌症相关成纤维细胞浸润显著相关。此外,抑制ERK1/2通过调节纤维化标志物FAP、FN1和COL1A1的表达,抑制了肿瘤细胞诱导的HSC迁移和侵袭增强。在肿瘤细胞和HSC脾脏共移植的异种移植小鼠模型中,抑制ERK1/2通过下调纤维化抑制了肝肿瘤形成,表明抑制ERK1/2可抑制肿瘤-基质相互作用。综上所述,我们的数据表明,抑制肿瘤相关HSCs中的ERK1/2可抑制肿瘤-基质相互作用和进展。此外,抑制ERK1/2可能是HCC治疗的一个潜在靶点。